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ABSTRACT
Introduction: Level 1 evidence supports the use of
supervised exercise to mitigate the adverse effects of
androgen deprivation therapy (ADT) in men with prostate
cancer. The data, however, have been generated in
controlled research settings and might not be transferable
to daily clinical practice. This article describes the design
of an ongoing prospective observational study to evaluate
the potential benefits of exercise in daily clinical practice.
Methods and analysis: Men diagnosed with prostate
cancer starting or already receiving ADT at our facility are
invited to participate in a 12-week exercise programme
implemented as the standard of care. Exclusion criteria
are opioid-demanding treatment for skeletal pain, an
Eastern Cooperative Oncology Group (ECOG) performance
status above 2 or the inability to perform floor and
machine exercises independently. The intervention
consists of an initial educational session of 1½ hours
followed by 12 weeks of group-based supervised training
two times a week. The focus of the exercise is progressive
resistance training in combination with aerobic training.
Participants are measured at baseline, after 12 weeks and
after 24 weeks as part of the programme. Primary
endpoints of this study are changes in physical fitness
evaluated by the 30 s Chair-Stand Test and Graded
Cycling Test with Talk Test. Secondary endpoints include
changes in quality of life, body composition and safety of
exercise. Inclusion started in August 2014, with 169
participants being included by December 2015.
Ethics and dissemination: The study has been
reviewed by the Scientific Ethical Committee of the Capital
Region of Denmark (reference number H-3-2013-FSP39).
The results of the study will be published in peer-reviewed
international journals and will be presented at national and
international conferences and symposiums.
Trial registration number: NCT02631681; Pre-results.
INTRODUCTION
Androgen deprivation therapy (ADT) is used
in the treatment of prostate cancer to
improve survival, delay disease progression
and to reduce cancer-related morbidity.1 At
the same time, the castrate levels of testoster-
one reached by ADT is associated with
several side effects, including loss of physical
ﬁtness, decreased quality of life (QoL) and
metabolic impairments, potentially leading
to treatment-induced morbidity.2–5 Often,
patients report increased fatigue and loss of
strength,6 7 supported by studies showing
ADT to decrease lean body mass as well as
muscle strength.8 Increased fat mass,
decreased insulin sensitivity and impaired
glucose metabolism are also well-known side
effects of ADT.9 10 It is therefore not surpris-
ing that population-based cohort studies
have reported an increased risk of bone frac-
ture, diabetes and possibly cardiovascular
disease (CVD) for men undergoing ADT
compared with non-ADT users.3–5 11
Exercise is recommended as a mitigating
treatment to the aforementioned adverse
effects, but results supporting the use of
exercise have been primarily generated in
Strengths and limitations of this study
▪ This trial will include a large sample size and
reports on the potential benefits of an exercise
intervention programme implemented in daily
clinical practice.
▪ This is the first larger trial to specifically report
on safety of resistance training for men with
prostate cancer and bone metastases.
▪ The trial includes a structured transition to
out-of-hospital training and a 12-week postinter-
vention follow-up, thereby addressing the poten-
tial difficulties of maintaining the positive effects
of exercise.
▪ The study lacks randomisation.
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controlled research settings and may not be transferable
to daily clinical practice. A recent systematic review and
meta-analysis investigated the effect of exercise in men
with prostate cancer and found exercise to improve
cancer-speciﬁc fatigue, QoL and physical ﬁtness and
function.12 The evidence was primarily obtained from
men with prostate cancer receiving ADT. This conclu-
sion is similar to those made in previous systematic
reviews exploring the effect of exercise in men with pros-
tate cancer undergoing ADT.13 14 The strongest data cur-
rently come from randomised trials where the
intervention arm has included supervised group-based
exercise combining resistance and aerobic training two
times a week for at least 12 weeks.15–17 A characteristic of
these positive trials has been adherence rates to the
intervention above 80% with interventions being per-
formed in a controlled research setting.15–17 Of note is
the trial by Bourke et al,16 in which they randomised 100
men undergoing long-term ADT to supervised com-
bined aerobic and resistance exercise or usual care.
Follow-ups were at 12 weeks with participants ending
intervention and additionally at 6 months. The research-
ers reported an adherence rate of 94% for the super-
vised exercise session, but after the withdrawal of
supervision, only 68% attended the follow-up at
6 months. In addition, they found a positive effect of
exercise on QoL measured postintervention, but the
beneﬁcial changes were not sustained at 6 months, high-
lighting the difﬁculty of maintaining continued exercise
and the beneﬁts thereof outside the controlled research
setting. This yields two unanswered questions if a similar
exercise programme were offered in a daily clinical
setting: (1) will similar positive effects on physical
ﬁtness, body composition and QoL be reachable? (2)
How can continued exercise after a 12-week intervention
be supported?
Another concern is that only a few previous studies
have included participants with bone metastases.16 18–20
Cormie et al20 performed a safety study including only
20 participants with bone metastases randomised to
resistance training or usual care and found resistance
training to be safe and well tolerated. However, exercises
targeting affected regions with bone metastases were
avoided. As many patients with disseminated prostate
cancer have or will develop multiple regions affected by
metastatic bone disease, the safety proﬁle of the study by
Cormie et al cannot be generalised to a broader group
of men with metastatic prostate cancer.
Hence, the aims of this study are as follows:
1. Examine the potential beneﬁts of exercise implemen-
ted in daily clinical practice on physical ﬁtness
(primary aim), QoL and body composition in men
with prostate cancer undergoing ADT.
2. Examine whether a structured transition to out-
of-hospital training can maintain the effects obtained
during supervised exercise intervention.
3. Assess the safety of progressive resistance training in
men with metastatic prostate cancer.
Our hypotheses are as follows: (1) a patient educational
session followed by a 12-week, supervised, group-based
progressive resistance training programme implemented
as the standard of care in a normal clinical setting will
improve physical ﬁtness, body composition and QoL. (2)
A structured transition to out-of-hospital training will
maintain the improvements in physical ﬁtness, body com-
position and patient QoL after the exercise intervention.
(3) Progressive resistance training using machines is also
a safe and feasible method of training for men with pros-
tate cancer and bone metastases.
This study will contribute to the current knowledge
regarding the beneﬁts of supervised exercise when
implemented in daily clinical practice and regarding the
potential difﬁculties when transitioning to out-of-hospital
training. Furthermore, a safety assessment of resistance
training for men with metastatic prostate cancer will be
made, which is critically needed for exercise to be gener-
ally recommended to men undergoing ADT.
METHODS AND ANALYSIS
This is a prospective observational study assessing an
exercise programme implemented as a standard of
care and routinely offered to men with prostate cancer
receiving ADT at our facility. A schematic overview of the
programme is depicted in ﬁgure 1. Participants are
recruited from a single centre and participate in a patient
educational programme of 1½ hours followed by
12 weeks of combined aerobic and resistance group-based
training. Participants will be evaluated at baseline, after
the exercise intervention and 12 weeks postintervention.
Participants
Men with prostate cancer undergoing ADT (orchiect-
omy, luteinising hormone-releasing hormone agonists or
antagonists) are invited to participate in the exercise
programme when attending their ambulant prostate
cancer controls at the Department of Urology, Herlev
and Gentofte University Hospital, Denmark. ADT must
be continued for at least 1 year forward. Thus, the
cohort consists of patients receiving ADT as an adjuvant
treatment in combination with external beam radiation
with curative intent and patients with advanced meta-
static prostate cancer. Patients undergoing chemother-
apy or second-line hormonal therapy with enzalutamide
or abiraterone in addition to ADT are also eligible for
participation. Exclusion criteria are opioid-demanding
treatment for skeletal pain, Eastern Cooperative
Oncology Group (ECOG) performance status above 2
or the inability to perform ﬂoor and machine exercises
independently. Patients with osteoporosis or a larger
bone metastatic burden assessed by the referring phys-
ician undergo a modiﬁed resistance training pro-
gramme. Prospective data collection began in August
2014 and is expected to continue until April 2017. The
number of participants, who have given consent to the
use of their healthcare data, was 169 in December 2015.
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Intervention
The programme is a standard of care (implemented at
our facility in December 2013) being offered to all our
patients receiving ADT who meet the criteria for partici-
pation. The intervention consists of an educational
session followed by 12 weeks of supervised group-based
exercise, ending with a structured out-of-hospital transi-
tion to continued exercise at a local training facility.
The educational session lasts 1½ hours, with lectures
from a urologist, nurse, dietitian and a physiotherapist
specially assigned to this task. Patients are invited to bring
a person of conﬁdence and to attend with the group they
are going to start the training programme with. During
the educational session, the natural history of prostate
cancer is covered as well as the rationale, indications and
methods of action for ADT. Furthermore, known physical
and psychological side effects of ADT, including the
implications of decreased libido and risks of osteoporosis,
diabetes and potential CVD, are addressed. The dietitian
lectures on the latest dietary recommendations according
to the Danish Health Authorities.
The following exercise programme consists of
1½ hours of supervised group-based training two times a
week for 12 weeks combining aerobic and resistance
training. This exercise routine has shown positive effects
on physical ﬁtness, body composition and QoL in
several randomised clinical trials.15–17 19 21 The main
focus of this programme is progressive resistance train-
ing using machines, following the guidelines for progres-
sion recommended by the American College of Sports
Medicine (ACSM).22 Each session is started with 15 min
of warm-up on a bike or stair walking followed by 60 min
of core, upper and lower body resistance training using
machines. The programme consists of seven exercises
targeting the major muscle groups of the body—leg
press, knee extensions, hamstring curls, chest press, low
row, sit-ups and back extension exercises. The progres-
sion model outlined in table 1 is used as a general
guideline to the individualised training progression. The
resistance training programme is supplemented by
aerobic exercise—∼6 min of exercise on a treadmill and
500 m of ergometer rowing. The resistance training is
tailored to the individual participant by the physiother-
apist to accommodate both his strength level and poten-
tial hazards such as osteoporosis and major regions of
metastatic disease. Close attention is paid if the phys-
ician has highlighted training restrictions in the patient
ﬁle due to comorbidity. In the presence of multiple
bone metastases or osteoporosis, a symptom-dependent
and very conservative approach to the progression of the
resistance training programme is adopted—that is, very
small increments in resistance. In addition to the super-
vised exercise, participants are encouraged to perform
one exercise session at home each week according to a
given programme provided in the patient educational
material; furthermore, both the participants and, if pos-
sible, their partners are instructed to stay generally phys-
ical active, deﬁned as daily non-strenuous activity of
10 000 paces.
The main behaviour change techniques according to the
the ‘Coventry, Aberdeen, and London—Reﬁned’
(CALO-RE) taxonomy23 24 used in this programme are:
‘provide information on consequences of behaviour in
general’, ‘goal setting (behaviour)’, ‘prompt practice’,
‘prompting generalisation of a target behaviour’,
‘provide instruction on how to perform the behaviour’,
‘model/demonstrate the behaviour’ and ‘plan social
support/social change’. The supervised group-based
training allows for verbal and visual instruction on how
to exercise and creates a platform where social support
and bonds between the participants are created.
Furthermore, the last two supervised training sessions are
performed at a local commercial ﬁtness centre to famil-
iarise participants with available facilities in the commu-
nity and to make a structured transition to out-of-hospital
training. Participants are encouraged to stay in contact
with one another and to continue the group-based train-
ing. For motivational purposes and to monitor the effect
on physical ﬁtness, the participants are tested at baseline
and after 12 and 24 weeks. Concurrently, the participants
are seen by a nurse to monitor changes in body compos-
ition as well as to address any concerns or questions the
participant might have regarding both his cancer treat-
ment and the exercise programme.
Measurements
All measurements of primary and secondary outcomes
are validated and widely used in clinical research. All
participants will be assessed at baseline, postintervention
and at the 24-week follow-up by specially trained nurses
and physiotherapists. A loss to follow-up of ∼10% at
24 weeks is expected primarily due to symptomatic
disease progression. Handling of missing data is covered
under sample size and statistical analysis.
Primary study endpoints
The primary endpoints of this study are a change in
workload (Watt) during the Graded Cycling Test with
Talk Test (GCT-TT) and a change in the number of
repetitions using the 30 s Chair-Stand Test (30s-CST).
Figure 1 Schematic overview of
the patient programme (blue
blocks) and the test visits (green
blocks).
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Both endpoints are measured as the within-person
change from baseline. GCT-TT is a submaximal exercise
test used to assess aerobic ﬁtness. It is not dependent on
the measurement of heart rate and is thus not inﬂu-
enced by medications or comorbidities potentially affect-
ing the heart rate variability. Excellent test/retest
reliability as well as an acceptable measurement error
and good responsiveness have been observed in cardiac
patients.25 26 Although not directly validated in patients
with prostate cancer, the GCT-TT is expected to be feas-
ible and reliable in this population because the patients
are expected to resemble the populations of cardiac
patients regarding age and comorbidity. The GCT-TT is
performed on a cycle ergometer as described by Nielsen
et al.25 A constant pedalling rate of 60 rounds per
minute is maintained throughout the test. After an
initial 2-min warm-up period with the exercise intensity
set to 15 W, a ramp protocol is applied with 15 W
increases every minute. During the last 10 s of each exer-
cise step of the test, a standard, 30-word text passage is
recited by the patients. Subsequently, they are asked,
‘Are you still able to speak comfortably?’. The following
predeﬁned answers can be given: ‘yes’, ‘unsure’ or ‘no’,
corresponding to a positive talk test (TT+), equivocal
talk test (TT±) and negative talk test (TT−). When the
answer ‘no’ is given, the test ends and the exercise inten-
sity is recorded.
The 30s-CST is used to assess functional perform-
ance/lower extremity muscle strength and endurance.27
The 30s-CST was chosen because it has previously been
used in patients with cancer undergoing a similar exer-
cise intervention mainly consisting of progressive resist-
ance training.28 The improvement in the 30s-CST result
(≈15–16%) corresponded well with the improvement in
isokinetic knee extension strength (≈12–18%) measured
by an isokinetic dynamometer.28 The 30s-CST is per-
formed according to the test manual described by Jones
et al,27 as follows: a chair with a seat height of 43 cm is
used. With arms crossed over the chest as many rises as
possible is performed in 30 s. The starting position is
sitting on the chair. A complete rise is recorded when
the knees and hips are fully extended in a standing pos-
ition and the next rise can begin when the patient has
assumed a sitting position on the chair seat without
touching the back rest. The command ‘ready, set, go’ is
used. The clock is started on ‘go’, and the number of
complete rises in 30 s is counted. The modiﬁed version
of the 30s-CST, in which the patients actively use the
armrests, is used in patients who are unable to stand up
only using the legs.29
Secondary study endpoints
Questionnaire-based assessments are conducted using the
validated European Organisation for Research and
Treatment of Cancer Quality of Life Core Questionnaire
(EORTC QLQC-30 V.3.0) and Quality of Life Prostate-
speciﬁc Questionnaire (EORTC QLQ-PR25).30 31
Speciﬁc endpoints of the EORTC QLQC-30 question-
naire are changed from baseline in global health status,
functional scales (physical functioning, role functioning,
emotional functioning, cognitive functioning and social
functioning) and fatigue measured by the symptom
scale. The EORTC QLQ-PR25 questionnaire is used to
measure changes from baseline in sexual activity
and sexual functioning. The latter will only be analysed
for patients who are sexually active at baseline.
Furthermore, the change in ADT-related symptoms is
assessed by the hormonal treatment-related symptoms
scale of the EORTC QLQ-PR25.
Table 1 Progression model for the resistance training over 24 sessions
Exercise session 1–2 3–6 7–13 14–21 22–24
Resistance training
Sets
Repetitions
2
15, 15
2
12, 12
3
12, 12, 12
3
10, 10, 10
3
8, 8, 8
Exercise intensity* 20 RM 15 RM 15 RM 12 RM 10 RM
Aerobic exercise—warm up†
Exercise mode Cycling/stairs Cycling/stairs Cycling/stairs Cycling/stairs Cycling/stairs
Exercise intensity ∼30–85% VO2-max: first low self-chosen intensity cycling or walking followed by either cycling intervals
or continuous stair climbing at ≈80% VO2-max
Exercise duration 15 min 15 min 15 min 15 min 15 min
Aerobic exercise—training‡
Exercise mode Treadmill and
rowing
Treadmill and
rowing
Treadmill and
rowing
Treadmill and
rowing
Treadmill and
rowing
Exercise intensity ≈80% VO2-max ≈80% VO2-max ≈80% VO2-max ≈80% VO2-max ≈80% VO2-max
Exercise duration 6 min/500 m 6 min/500 m 6 min/500 m 6 min/500 m 6 min/500 m
*20 RM= the weight that can be lifted 20 times before repetition failure.
†Performed on a stationary bike or by climbing the stairs to the 23rd floor (560 steps).
‡Walking or running on the treadmill depending on the fitness level. During ergometer rowing the patients try to set a new personal best on
every occasion.
RM, repetition maximum; VO2-max, maximal oxygen consumption.
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To examine changes in body composition, nurses
measure the body mass index (BMI, kg/m2) and the
waist circumference (WC) and hip circumference (HC)
in centimeters. A secondary end point is the change
from baseline in BMI, WC, HC and waist–hip ratio.
These changes do not reﬂect the beneﬁts of exercise on
muscle mass. However, waist–hip ratio and WC are used
to assess change in fat distribution and abdominal
adipose tissue, which are risk factors of the metabolic
syndrome, diabetes mellitus and CVD.32 WC is measured
according to the WHO guidelines midway between the
inferior margin of the last rib and the crest of the ilium,
in the horizontal plane.33 Similarly, HC is measured
around the buttocks in the horizontal plane at the level
of maximum extension.
Blood pressure (systolic and diastolic) is measured at
each visit after a 10 min seated rest. Changes in systolic
and diastolic blood pressure from baseline will be investi-
gated separately.
Safety of exercise is measured by the prospective record-
ing of any serious adverse events in relation to training.
A serious related adverse event is deﬁned in accordance
with the European Medicine Agency (EMA) as any
undesirable experience associated with exercise that
results in death, is life-threatening, requires hospitalisa-
tion or prolongation of existing hospitalisation, results in
persistent or signiﬁcant disability or results in some
other medically important condition. Minor adverse
events such as muscle strains or muscle soreness after
exercise will not be reported.
Compliance with the programme will be reported as
attendance at the supervised group training sessions.
The ability of participants to perform the exercises as
prescribed, that is correct intensity and number of repe-
titions, will be reported as percentage of exercises
during attended sessions completed as prescribed.
Patient self-reports, completed during each session, on
intensity and the number of repetitions done for each
exercise will be used for this analysis. Furthermore, con-
tinued exercise after the ended intervention will be
reported as either yes or no and also relies on patient
self-reports.
Sample size and statistical analysis
An inclusion cut-off date has been set to 15 October
2016 with expectations of having included ∼230 partici-
pants. Previous larger randomised trials investigating the
effects of exercise in men with prostate cancer have
included ∼100 participants.16 21 34 As we mean to evalu-
ate the safety of exercise and there is no control arm, we
have chosen a substantially larger sample size. Minimal
sample size calculations to detect a clinically signiﬁcant
change have been carried out for the primary end-
points. Data from an in-house project have shown clin-
ical signiﬁcance within-person change in the GCT-TT at
13 W and the SD of the change at 18 W.26 As we expect
to perform multiple tests, the α-level in the sample size
calculation is set at 0.005, two-sided, to allow correction
for multiple testing. With a power at 0.80, a minimal
sample size of 30 participants is required. For the
30s-CST, the clinically signiﬁcant change was set at 2.6
repetitions with an SD at 2.2 in accordance with a previ-
ous study by Wright et al.35 With a power at 0.80 and a
signiﬁcance level at 0.005, a sample size of 13 is
necessary.
Linear mixed-effect models or Friedman tests will be
used for analyses of data with multiple time points.
Clinically relevant covariates such as age, exercise com-
pliance (high compliance is predeﬁned as 75% attend-
ance), continued exercise postintervention, duration of
ADT, baseline BMI, treatment for castration-resistant
prostate cancer other than ADT and known comorbid-
ities (CVD, diabetes mellitus, hypertension, dyslipidae-
mia and osteoporosis) will be included in the analyses to
assess effect modiﬁcation (interaction). If a signiﬁcant
interaction is found we will perform subgroup analysis
on the covariate. Missing data will be handled by the
mixed-effect models, assuming the data are missing at
random. A sensitivity analysis for the missing-at-random
assumption will be performed. Secondary, and more
explorative, analyses will include comparisons of the
baseline to the 12-week follow-up and of the 12-week to
the 24-week follow-up.
p Values will be two-sided and p values below 0.05 will
be considered signiﬁcant. Statistical calculations will be
performed using SAS 9.4 (SAS Institute, Cary, North
Carolina, USA) or a similar software. Statistical planning
was conducted in cooperation with a biostatistician.
ETHICS AND DISSEMINATION
The ethical committee did not ﬁnd approval to be
required. All participants have provided written
informed consent. The study has been registered on
Clinicaltrials.gov (NCT02631681). Results of the study
will be published in peer-reviewed international journals
or otherwise made publicly available and will be pre-
sented at national and international conferences and
symposiums irrespective of the outcomes. Completion of
this study is expected by spring 2017, and dissemination
of the results will begin as soon as possible thereafter.
DISCUSSION
The aim of this study is to report results on exercise ben-
eﬁts in a supervised setting and when participants transi-
tion from supervised to individual training for men with
prostate cancer receiving ADT. The strength of this study
is that the intervention is part of the daily clinical prac-
tice as a standard of care in our department. Therefore,
the participants are also comparable to those seen by
the treating physicians. The present study with a large
sample size will also answer the important question of
whether resistance training is safe for men with bone
metastases, thereby making recommendations on exer-
cise programmes for men undergoing ADT, as a whole,
easier. The most important limitation of the study is that
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we do not have a control group as a reference because
we are reporting data on an intervention implemented
as the standard of care. As we are examining the within-
person change over time, we expect the latter to be a
potential inﬂuential factor. Participants with metastatic
prostate cancer are with the 24-week follow-up prone to
get worse from their disease and potentially develop
further ADT-related side effects. Thus, time-related wor-
sening can in itself hide a positive effect of the exercise
intervention. However, this will only strengthen a poten-
tial signiﬁcant positive result. Successful outcomes of
this study will support the implementation of exercise
programmes for men with prostate cancer receiving
ADT in clinical practice.
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